Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript. The company discussed increases in net debt primarily due to payments related to a DOJ settlement and the GLS divestment transaction, not new fundraising. Glenmark is focusing on operational performance improvements and margin expansion rather than raising new funds. No specific guidance or comments on equity issuance or debt raising were provided during the Q2 FY24 earnings call. The management appears confident in cash flow improvements in H2 FY24 from business performan

Any current/future capex/capital investment/strategic investment?

Consolidated total asset addition in Q2 FY24 was Rs.249.7 crores, including Rs.162.8 crores in tangible assets and Rs.86.9 crores in intangible assets (Page 7). Ongoing investment in Ichnos: Glenmark invested Rs.1,613 million (~US$19.6 million) in Q2 FY24 and Rs.3,030 million (~US$36.8 million) in H1 FY24, focusing on innovation and strategic growth (Page 7). No specific new capex guidance mentioned for future quarters, but the company is focusing on operational improvements such as remediation completion at Monroe and market expansions. Mention of launching new products and expanding presence

Future growth expectations in sales/revenue/volumes?

US business: Expected to strengthen in coming years with new product filings (e.g., Fluticasone MDI filing planned between Q4 and Q1) and respiratory product launches; however, near-term outlook uncertain due to market conditions. Europe and Rest of World (ROW): Strong, broad-based growth expected; Europe targeting 15-20% minimum growth with further margin expansion; ROW (including Asia, Latin America, Middle East, Africa) performing well with key approvals driving growth (e.g., in Brazil, Russia). India: Anticipated sustained growth of 12-15% over the next three years, driven by RX (respi

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark expects significant improvement in EBITDA margins, targeting close to 19% by FY25, driven by: - 2% margin expansion from lower innovative R&D spend. - Additional margin gains from RYALTRIS and operating leverage in Europe and Latin America. PAT margins are anticipated to see a notable uplift in FY25 due to lower interest, depreciation, and tax expenses post GLS transaction. US business is expected to recover with new launches (including respiratory products) and the return of Monroe from next year. India business is projected to sustain 12-15% growth over the next 2-3 years, led b

Glenmark Pharma.Q2 FY24Pharmaceuticals & Biotechnology

Glenmark Pharma. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,331P/E: 21.5Market Cap: ₹67.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

US business: Expected to strengthen in coming years with new product filings (e.g., Fluticasone MDI filing planned between Q4 and Q1) and respiratory product launches; however, near-term outlook uncertain due to market conditions.
Europe and Rest of World (ROW): Strong, broad-based growth expected; Europe targeting 15-20% minimum growth with further margin expansion; ROW (including Asia, Latin America, Middle East, Africa) performing well with key approvals driving growth (e.g., in Brazil, Russia).
India: Anticipated sustained growth of 12-15% over the next three years, driven by RX (respiratory, cardiac, dermatology, diabetes segments), OTC, and institutional business growth.
Glenmark Life Sciences (GLS): being divested, so future consolidation impact to be considered.
Overall: Expectation of strong portfolio with multiple approvals, operating leverage, and margin improvements supporting sales and volume growth across markets.

Margin guidance

Category 1

Glenmark expects significant improvement in EBITDA margins, targeting close to 19% by FY25, driven by:
- 2% margin expansion from lower innovative R&D spend.
- Additional margin gains from RYALTRIS and operating leverage in Europe and Latin America.
PAT margins are anticipated to see a notable uplift in FY25 due to lower interest, depreciation, and tax expenses post GLS transaction.
US business is expected to recover with new launches (including respiratory products) and the return of Monroe from next year.
India business is projected to sustain 12-15% growth over the next 2-3 years, led by respiratory, cardiac, dermatology, and OTC segments.
ROW and Europe are robust growth drivers with expected EBITDA margin improvements adding approximately 1-2% each year.
Overall, FY25 is considered a transition year with strong positive earnings trajectory post GLS divestment and remediation cost reductions.

See what Glenmark Pharma. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript.
The company discussed increases in net debt primarily due to payments related to a DOJ settlement and the GLS divestment transaction, not new fundraising.
Glenmark is focusing on operational performance improvements and margin expansion rather than raising new funds.
No specific guidance or comments on equity issuance or debt raising were provided during the Q2 FY24 earnings call.
The management appears confident in cash flow improvements in H2 FY24 from business performance and expects to manage existing obligations without new fundraises.

Order book

The transcript provided in the document does not explicitly mention the current or expected order book or pending orders for Glenmark Pharmaceuticals. However, some relevant points related to business outlook and product pipeline include: - Glenmark has a healthy portfolio of products being filed, supporting a strong US business outlook in coming years, subject to approvals. - The company plans to file 10 to 12 ANDAs (Abbreviated New Drug Applications) in FY24. - The marketing portfolio as of September 30, 2023, includes 185 generic products authorized in the US and 51 ANDA applications pending. - Several launches in Q3 FY24, including Varenicline tablets via partnership and three injectables, expected to boost sales. - Growth drivers include respiratory, cardiac, dermatology, and OTC segments across India, Europe, and ROW markets. No direct commentary on order book or specific pending orders volume is provided in the transcript.

See what Glenmark Pharma. management said on order book — free account, 30 seconds.

Capex plans

Yes

Consolidated total asset addition in Q2 FY24 was Rs.249.7 crores, including Rs.162.8 crores in tangible assets and Rs.86.9 crores in intangible assets (Page 7).
Ongoing investment in Ichnos: Glenmark invested Rs.1,613 million (~US$19.6 million) in Q2 FY24 and Rs.3,030 million (~US$36.8 million) in H1 FY24, focusing on innovation and strategic growth (Page 7).
No specific new capex guidance mentioned for future quarters, but the company is focusing on operational improvements such as remediation completion at Monroe and market expansions.
Mention of launching new products and expanding presence in key markets like US (respiratory and injectables), Europe, Latin America, and India suggests continued strategic investments in portfolio and geographic diversification (Pages 9, 12, 13).
GLS transaction expected to be recognized in Q3 FY24; post-divestment, capital allocation may shift (Page 7).

Track Glenmark Pharma. — get its next earnings analysis in your feed

How does Glenmark Pharma. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGlenmark Pharma.

Rev 3Mar 1

See where Glenmark Pharma. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Glenmark Pharma. rank in Pharmaceuticals & Biotechnology?

Compare Glenmark Pharma. against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Glenmark Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →